Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Healthcare Medical Devices
DIAGNOS Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for modifying and developing of applications, such as Computer Assisted Retina Analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time... see more

Recent & Breaking News (TSXV:ADK)

DIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certification

GlobeNewswire 9 days ago

DIAGNOS Inc. to Present at the AI & Technology Hybrid Investor Conference April 11th

GlobeNewswire April 9, 2024

DIAGNOS Announces Grant of Stock Options

GlobeNewswire April 3, 2024

DIAGNOS Welcomes Dr. Philippe Couillard to its Board of Directors

GlobeNewswire April 2, 2024

DIAGNOS Announces Closing of Second and Final Tranche of Private Placement

GlobeNewswire March 22, 2024

DIAGNOS Announces Grant of Stock Options

GlobeNewswire March 4, 2024

DIAGNOS Welcomes Mr. Michael Braeuel to its Board of Directors

GlobeNewswire February 29, 2024

DIAGNOS Announces Closing of First Tranche of Private Placement

GlobeNewswire February 27, 2024

Diagnos Announces Variation in One Insider Ownership of Common Shares

GlobeNewswire February 23, 2024

DIAGNOS recognized as a Top TSX Venture Exchange Company

GlobeNewswire February 21, 2024

DIAGNOS Appoints New Chief Operating Officer

GlobeNewswire January 16, 2024

Canadian Investment Regulatory Organization Trade Resumption - ADK

Canada NewsWire December 11, 2023

DIAGNOS Secures Exclusive Distribution Agreement for Canada with EssilorLuxottica, a Global Leader in Vision Care

GlobeNewswire December 11, 2023

Canadian Investment Regulatory Organization Trading Halt - ADK

Canada NewsWire December 8, 2023

DIAGNOS Announces Closing of Private Placement

GlobeNewswire December 4, 2023

DIAGNOS AI Retina Analysis is being deployed across Canada's Largest Specialist Care Provider in Diabetes & Endocrinology

GlobeNewswire October 5, 2023

DIAGNOS Announces Closing of Private Placement and Exercise of Stock Warrants

GlobeNewswire May 18, 2023

DIAGNOS and IRIS, The Visual Group strengthen partnership with the launch of "IRIS-ai powered by DIAGNOS"

GlobeNewswire May 17, 2023

DIAGNOS and ÉTS Unveil a Method to Adapt Deep Learning Algorithms According to the Diversity of Contexts

GlobeNewswire February 28, 2023

DIAGNOS and ETS to Present Ground-breaking Research on Mass Screening for Macular Edema at ARVO 2023

GlobeNewswire February 14, 2023